Company intelligence / Profile preview

Shield Therapeutics plc

London, England, United Kingdomshieldtherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

The company’s lead product, ACCRUFeR®/Feraccru® (ferric maltol), has demonstrated efficacy and tolerability in a range of clinical trials for iron deficiency with or without anemia. It has been launched commercially in the US and Europe through partnerships and licensing agreements.[4] The company remains on track to be cash flow positive by the end of 2025.[8] FY group revenues were reported ahead of expectations at $32.2 million for the most recent year.[10]

Therapeutic areas: Hematology
Modalities: Small molecules (ferric maltol)
Industry: Biotech

Drug pipeline

4 assets

ferric maltol

Approved

3 more assets in the full pipeline.

Partnerships

Viatris – exclusive multi-year collaboration agreement for US commercialization of Accrufer®/Feraccru® [4].Norgine B.V. – licensee/commercialization partner for UK/EU [4].

Beyond the preview

Go deeper on Shield Therapeutics plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shield Therapeutics plc.